COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma

Protocol No
NOVARTIS-CWVT078A12101
Principal Investigator
Parameswaran Hari
Phase
I
Summary
WVT078 is a type of drug called a “bispecific antibody”. WVT078 works by activating your immune system to attack multiple myeloma cells. This is similar to how your immune system protects you by attacking bacteria and viruses like the cold or flu virus. WVT078 attaches to a target on multiple myeloma cancer cells called BCMA, and at the same time, attaches to a target on an immune system cell called a CD3 T cell. By bringing your immune system cells to the multiple myeloma cells, your immune system can attack the cancer. WHG626 is a drug that may make WVT078 work better in two ways; by increasing the amount of BCMA on multiple myeloma cell and by increasing the amount of WVT078 able to attach to BCMA on myeloma cells.
Description
The purpose of this study is to find the best dose of WVT078 or WVT078 combined with WHG626 that can be given to patients with multiple myeloma and to evaluate how well the treatment might work in treating patients with this type of cancer. This is the first time WVT078 or WVT078 combined with WHG626 are being used in humans. WHG626 has been studied previously in patients with different types of cancer than yours
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL